Recently, the Office of the National Leading Group for the Recognition of High‑Tech Enterprises released the "Publicity of the Second Batch of High‑Tech Enterprises Recognized and Filed by Sichuan Provincial Recognition Institutions in 2025." Chengdu West China Clinical Research Center Co., Ltd. (hereinafter referred to as "WCCR") successfully passed the re‑certification. Following its initial recognition as a National High‑Tech Enterprise in 2022, WCCR has once again earned this prestigious national qualification based on its solid technological strength and innovation capabilities.
Innovation is the primary driving force for development. Since its establishment, WCCR has adhered to the development philosophy of "innovation‑driven, technology‑led," steadily advancing the construction of platforms such as clinical research services and public technology services for the biomedical industry, and actively promoting the translation of innovative biomedical scientific achievements into clinical applications. This re‑certification not only serves as a comprehensive assessment of WCCR's continuous innovation, enterprise management, and achievement transformation capabilities, but also as a testament to our commitment to "Advancing Clinical Research, Propelling Medical Innovation."
Looking ahead, WCCR will continue to uphold its core values of "professionalism, innovation, integrity, and win‑win cooperation," focus on the needs of the biomedical industry, attract and nurture high‑level scientific talents, target key frontiers in biomedicine, strengthen the construction of high‑level R&D service platforms, and help translate more innovative medical products into practice — moving steadily forward on the path of integrating innovation and service excellence.
